So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients
- PMID: 26671969
- DOI: 10.1161/CIRCGENETICS.115.001256
So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients
Keywords: Editorials; LDLR; PCSK9; cardiovascular disease; hypercholesterolemia; lipoprotein; pharmacology; treatment.
Comment on
-
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.Circ Cardiovasc Genet. 2015 Dec;8(6):823-31. doi: 10.1161/CIRCGENETICS.115.001129. Epub 2015 Sep 15. Circ Cardiovasc Genet. 2015. PMID: 26374825 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
